ClinicalTrials.Veeva

Menu
R

Research Carolina Elite | Denver, NC

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

TAK-861
E2086
Astegolimab
Pitolisant
TAK-994
AD109
Deudomperidone
PBI-0451
BRII-296
CIN-102

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 24 total trials

A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout

The primary objective of this trial is to evaluate the effect of pegloticase 18 mg subcutaneously (SC) every two weeks with methotrexate (MTX) versus...

Enrolling
Uncontrolled Gout
Drug: Pegloticase
Drug: Methotrexate

This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled clinical study to assess the efficacy and safety of HBS-...

Enrolling
Cataplexy
EDS
Drug: HBS-301
Other: Placebo

The main aim is to evaluate the safety and tolerability of TAK-861 in participants with type 1 narcolepsy, who were exposed to previously tested dose...

Enrolling
Narcolepsy Type 1
Drug: TAK-861

This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COP...

Active, not recruiting
Chronic Obstructive Pulmonary Disease (COPD)
Drug: Astegolimab
Drug: Placebo

The primary purpose of this study is to evaluate the optimal doses of E2086 compared to placebo in participants with narcolepsy for reduction of exce...

Enrolling
Narcolepsy
Drug: E2086
Drug: Placebo
Status recently updated

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmo...

Enrolling
Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Astegolimab

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only
OSA
Drug: Aroxybutynin and Atomoxetine

Trial sponsors

Takeda logo
Amgen logo
Apnimed logo
Eisai logo
Roche logo
H
Brii Biosciences logo
C
H
M

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems